4 completed, 1 unknown. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow EmeraMed: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NBMI Treatment in Patients With Mercury Toxicity (N1, N3-bis(2- mercaptoethyl)isophthalamide), Excipients microcrystalline cellulose, silica and magnesium stearate - Mercury Poisoning | Phase 2 / Phase 3 | Unknown | EmeraMed | 116 | 2023-11-22 | 2024-03-12 |
| Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation Emeramide - Beta Thalassemia Major | Phase 2 | Completed | EmeraMed | 13 | 2019-11-21 | 2021-08-26 |
| Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) NBMI, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Completed | EmeraMed | 20 | 2019-09-16 | 2021-09-23 |
| NBMI - Clinical Study on COPD Emeramide, Placebo - COPD, COPD Bronchitis | Phase 2 | Completed | EmeraMed | 12 | 2017-01-01 | 2021-03-05 |
| Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication Emeramide, Placebo - Mercury Poisoning | Phase 2 | Completed | EmeraMed | 36 | 2015-08-01 | 2021-03-08 |
Mercury Poisoning (2) · Multiple System Atrophy (1) · Pulmonary Disease, Chronic Obstructive (1) · Supranuclear Palsy, Progressive (1) · beta-Thalassemia (1)
N,N'-Bis(2-mercaptoethyl)isophthalamide (3) · Silicon Dioxide (1) · stearic acid (1)
Albania (1) · Colombia (1) · Ecuador (1) · Slovenia (1)
Andres Cadena-Bonfanti, MD (1) · Augusto Focil Baquerizo, MD (1) · Tanja Turk, M. Pharm (1)